Skip to main content Accessibility help
×
Home

Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom

  • A. GAUTHIER (a1), J. BREUER (a2), D. CARRINGTON (a3), M. MARTIN (a1) and V. RÉMY (a4)...

Summary

Recent information on epidemiology and management of herpes zoster (HZ) and post-herpetic neuralgia (PHN), a painful complication of HZ, is scarce. The objective of this study was to document the burden of HZ and PHN in the United Kingdom. This retrospective analysis of the UK General Practice Research Database aimed to estimate HZ incidence and proportion of HZ patients developing PHN and to assess management costs in immunocompetent individuals aged ⩾50 years. A cohort of 27 225 HZ patients was selected, corresponding to an incidence of 5·23/1000 person-years. Respectively 19·5% and 13·7% of patients developed PHN at least 1 and 3 months after HZ diagnosis. Mean direct cost was £103 per HZ patient and £341 and £397 per PHN episode (1- and 3-month definition respectively). Both HZ and PHN costs increased markedly with pain severity. This study confirms that HZ and PHN are frequent and costly diseases in the United Kingdom.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom
      Available formats
      ×

Copyright

Corresponding author

*Author for correspondence: A. Gauthier, i3 Innovus, 3rd floor, Beaufort House, Cricket Field Road, Uxbridge, Middlesex UB8 1QG, UK. Email: aline.gauthier@i3innovus.com

References

Hide All
1. Oster, G, et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. Journal of Pain 2005; 6: 356363.
2. Johnson, RW, Dworkin, RH. Treatment of herpes zoster and postherpetic neuralgia. British Medical Journal 2003; 326: 748750.
3. Jung, BF, et al. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004; 62: 15451551.
4. Schmader, K. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clinical Journal of Pain 2002; 18: 350354.
5. Miller, E, Marshall, R, Vurdien, J. Epidemiology, outcome and control of varicella-zoster infection. Reviews in Medical Microbiology, 1993; 4: 222230.
6. Brisson, M, et al. Epidemiology of varicella zoster virus infection in Canada and in the United Kingdom. Epidemiology and Infection 2001; 27: 305314.
7. Cunningham, AL, Dworkin, RH. The management of post-herpetic neuralgia. British Medical Journal 2000; 321: 778779.
8. Donahue, JG, et al. The incidence of herpes zoster. Archives of Internal Medicine 1995; 155: 16051609.
9. Bowsher, D. The lifetime occurrence of herpes zoster and prevalence of postherpetic neuralgia: a retrospective survey in an elderly population. European Journal of Pain 1999; 3: 335342.
10. Edmunds, J, Brisson, M, Rose, JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001; 19: 30763090.
11. Opstelten, W, et al. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Family Practice 2002; 19: 471475.
12. Scott, FT, et al. The burden of Herpes Zoster: a prospective population based study. Vaccine 2006; 24: 13081314.
13. Hope-Simpson, R. Postherpetic neuralgia. Journal of Royal College of General Practitioners 1975; 18: 2533.
14. Oxman, MN, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine 2005; 352: 22712284.
16. Curtis, L, Netten, A. Unit Costs and Health and Social Services 2005. Personal Social Services Research Unit, 2005.
17. British National Formulary (http://www.bnf.org). Accessed 20 June 2006.
19. UK National Statistics (www.statistics.gov.uk). Accessed 20 June 2006.
20. Insinga, R, et al. The incidence of Herpes Zoster in a United States Administrative Database. Journal of General Internal Medicine 2005; 230: 748753.
21. Thomas, S, Hall, A. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infectious Diseases 2004; 4: 2633.
22. Bebbington, A, Darton, R, Netten, A. Care homes for older people, volume 2. Admissions, needs and outcomes. The 1995/96 National Longitudinal Survey of Publicly-Funded Admissions PSSRU (http://www.pssru.ac.uk/pdf/chop2.pdf). Accessed 13 February 2008.
23. Alper, B, Lewis, P. Does treatment of acute Herpes Zoster prevent or shorten postherpetic neuralgia? A systematic review of the literature. Family Practice 2000; 49: 255264.
24. Opstelten, W et al. Gender as an independent risk factor for herpes zoster: a population-based prospective study. Annals of Epidemiology 2006; 16: 692695.
25. Fleming, D, et al. Gender difference in the incidence of shingles. Epidemiology and Infection 2004; 132: 15.
26. Coplan, PM, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. Journal of Pain 2004; 5: 344356.
27. Chidiac, C, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clinical Infectious Diseases 2001; 33: 6269.
28. Davies, L, et al. The cost of treatment for post-herpetic neuralgia in the UK. Pharmacoeconomics 1994; 6: 142148.
29. Katz, J, et al. Acute pain in herpes zoster and its impact on health-related quality of life. Clinical Infectious Diseases 2004; 39: 342348.
Type Description Title
WORD
Supplementary materials

Gauthier Supplementary Material
Supplementary Appendix

 Word (77 KB)
77 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed